Transgene SA
PAR:TNG
Transgene SA
PAR:TNG
Price:
1.24 EUR
1.64%
Updated:
May 3, 2024
Section:
Relative Value
The Relative Value of one
TNG
stock under the Base Case scenario is
4.41
EUR.
Compared to the current market price of 1.24 EUR,
Transgene SA
is
Undervalued by 72%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TNG
Relative Value
Base Case
4.41
EUR
Undervaluation 72%
Valuation Multiples
Multiples Across Competitors
TNG Competitors Multiples
Transgene SA Competitors
Transgene SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Transgene SA
PAR:TNG
|
122.7m EUR | 16.3 | -5.6 | -4.3 | -4.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
149.1B USD | 5.3 | 22.2 | 16.5 | 24.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.1B USD | 10.4 | 28.5 | 22.8 | 23.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
102.6B USD | 7.8 | 25.9 | 17.4 | 19.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.2 | 35.4 | 21.4 | 26.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.4B USD | 3 | 168.2 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48B USD | 7 | -10.2 | -11 | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 3.2 | 26.6 | 13.7 | 17.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
